Leadership1 distinct publisher3 min readPublished
Radial's purchase of Mindful Health Solutions' management services organisation creates a single operator for emerging brain treatments. Payer coverage, not clinical enthusiasm, sets its pace.
The Board Room · Leadership desk
Compiled by The Board RoomSomething wrong?How this is made
An MSO purchase is a purchase of the back office. Radial did not buy a clinical breakthrough; it bought the entity that bills, schedules and runs workflow behind the practices, and Radial co-founder and chief scientific officer Dr. Owen Muir was direct about the thesis in his interview with Forbes: Mindful Health Solutions already shared the care philosophy and lacked the technology to execute it [5]. That makes the integration a revenue-cycle and software project before it is a medical one. The work Radial says is already under way reads accordingly: MRI centre partnerships to widen access to Magnus Medical's SAINT, clinical trial operations standardised so they can be copied to new sites, and Radial's own billing and clinical workflow infrastructure pushed across the enterprise [14].
The arithmetic is worth stating plainly, because the press framing of scale invites the wrong picture. Over 100 clinicians across 27 clinics is fewer than four clinicians per site [16]; 27 clinics across seven states is under four sites per state [17]. This is not market dominance anywhere. The leverage is different in kind: a device or drug developer that wants a protocol in front of patients can now switch it on in 27 locations through one negotiation rather than 27, and Radial's stated ambition is to be ready for "any new intervention coming to market" [3].
What governs the speed is stated in the source and easy to skim past. The currently available offerings, including BrainsWay's FDA-cleared SWIFT protocol, Ampa One TMS, PRISM EEG-fMRI neurofeedback for PTSD, ProlivRx and SAINT, will be expanded into the acquired network "based on payer coverage and other factors" [7]. So the customer whose behaviour decides the rollout is the payer, whatever the patient-as-customer language around it [5]. SAINT needs an fMRI to target treatment [7], which is precisely the sort of cost a coverage policy either absorbs or does not.
Follow the money in the same source and the strategy resolves further. TMS is growing at nearly eight percent a year and is on course to exceed half a billion dollars by 2030, while esketamine and ketamine treatments are already estimated at $1.5 billion and $3.5 billion [8][9]. The drug-administration line is therefore roughly ten times the projected 2030 device line [18]. That is the commercial logic behind Muir's expectation that psilocybin will be approved for depression and cluster headache [11], and behind a network that has already delivered Spravato and ketamine at both companies [13].
One caution on the evidence. The Forbes account quotes Radial's CEO and its chief scientific officer, and reports no purchase price, no deal terms and no named payer contract [19]. Anyone sizing this as a counterparty is working from the buyer's description of its own thesis.
Ranked by verification strength, evidence, and original report placement.
Radial announced the acquisition of Mindful Health Solutions' management services organisation (MSO), creating a combined network of 27 clinics and over 100 clinicians across seven states specialising in bringing emerging psychiatry and neurology treatments to patients.
The newly combined company will operate under the Radial brand with an integrated leadership team led by Radial CEO John Capecelatro.
Capecelatro said of the acquisition and the resulting scale of the network: "we're really excited about deliberately, carefully, and thoughtfully supporting any new intervention coming to market."
Radial chief scientific officer Dr. Owen Muir described two goals for the combined network's patient encounters: faster time to the first appointment, and making a broader range of treatments available to more people.
Muir said the aim "wasn't just to acquire a bunch of clinics" but "to scale our technology workflow and philosophy of patient care", adding that Radial thinks of every patient as the customer and that Mindful Health Solutions did too but "just didn't have the technology necessary to make it the kind of seamless customer experience that patients expect in 2026."
Expanding access to accelerated transcranial magnetic stimulation was foundational to Radial's launch last year, and the new footprint will scale that approach by retrofitting it to Mindful Health Solutions' practice sites.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Single interested source, no terms
All substantive claims come from one contributor article built on interviews with two Radial executives. The transaction itself and the footprint are specific and checkable in principle, but there is no price, no financing, no seller or payer voice, and the market-size and regulatory claims are self-citations from the author's prior column with no provider or methodology named.
Real footprint, unproven throughput
Adoption is grounded in a disclosed, non-trivial delivery footprint and named integration workstreams already in progress, plus an active trial partnership. It is capped because per-site staffing is thin, no patient volumes, revenue, or payer coverage wins are quantified, and the interventional menu expansion is a plan gated on reimbursement rather than a completed rollout.
Market-reshaping framing outruns disclosure
The framing - reshaping the brain medicine market, readiness for 'any new intervention,' and a coming psilocybin era - runs well ahead of what is shown: a modest 27-site network, no economics, no payer agreements, and an executive stance that coverage policy matters less than what it 'should be or will be.' The gap is moderate rather than extreme because the acquisition, footprint, and integration workstreams are real and specifically described.
Acquirer-controlled narrative
Every quote belongs to the acquiring company's CEO and chief scientific officer, published days after the deal, on a contributor platform, with no counterparty, payer, clinician, or independent expert included. The vendors whose protocols are named benefit from the expansion narrative, and the market-size framing is recycled from the author's own earlier piece, so the incentive load on the storyline is high.
Transaction facts firm, everything else soft
Confidence is limited by single-publisher, single-source coverage. The existence of the acquisition, the brand and leadership arrangement, the disclosed footprint, and the named integration workstreams are internally consistent and specific; the market sizing, regulatory characterisation, and approval forecast are not verifiable from the supplied material, and no second account exists to corroborate or contradict.
Distinct publishers with included, body-backed reporting in this cluster.
forbes.com
1 article · August 25, 2026